Novartis Ag (NVS) Share-based Compensation (2009 - 2012)
Novartis Ag recorded quarterly Share-based Compensation of $132.0 in Q2 2012, down 53.36% quarter-over-quarter from $283.0 in Q1 2012, and down 45.9% year-over-year from $244.0 in Q3 2011.
Novartis Ag's Share-based Compensation history runs 4 years deep, the most recent figure standing at $132.0 for Q2 2012.
- In Q2 2012, Share-based Compensation fell 45.9% year-over-year to $132.0; the TTM figure through Jun 2012 stood at $867.0 (up 18.77% YoY), while the FY2011 annual figure was $806.0, up 34.56% from the prior year.
- Share-based Compensation came in at $132.0 for Q2 2012 at Novartis Ag, down from $283.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $283.0 in Q1 2012 to a low of $132.0 in Q2 2012.
- A 4-year average of $190.38 and a median of $172.5 in 2010 frame the typical range for Share-based Compensation.
- On a YoY basis, Share-based Compensation climbed as much as 65.5% in 2012 and fell as far as 45.9% in 2012.
- Novartis Ag's Share-based Compensation stood at $170.0 in 2009, then climbed by 2.35% to $174.0 in 2010, then advanced by 19.54% to $208.0 in 2011, then tumbled by 36.54% to $132.0 in 2012.
- According to Business Quant data, Share-based Compensation over the past three periods registered $132.0, $283.0, and $208.0 for Q2 2012, Q1 2012, and Q4 2011 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 161.00 Mn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 300.00 Mn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 444.00 Mn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 185.00 Mn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 75.00 Mn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 218.00 Mn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 272.00 Mn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 146.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2012 | 132.00 |
| Jun 30, 2012 | 132.00 |
| Mar 31, 2012 | 283.00 |
| Mar 31, 2012 | 283.00 |
| Dec 31, 2011 | 208.00 |
| Dec 31, 2011 | 208.00 |
| Jun 30, 2011 | 244.00 |
| Jun 30, 2011 | 244.00 |
| Mar 31, 2011 | 171.00 |
| Mar 31, 2011 | 171.00 |
| Dec 31, 2010 | 174.00 |
| Dec 31, 2010 | 174.00 |
| Mar 31, 2010 | 141.00 |
| Mar 31, 2010 | 141.00 |
| Mar 31, 2009 | 170.00 |
| Mar 31, 2009 | 170.00 |